Why InfuSystems Holdings (INFU) Might be Well Poised for a Surge
InfuSystems Holdings, Inc. (INFU) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can InfuSystems Holdings (INFU) Climb 79.52% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 79.5% in InfuSystems Holdings (INFU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Investors Undervaluing InfuSystems Holdings (INFU) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Buy Stocks for August 8th
INFU, RIGL, TROW, MITSY and NTRS have been added to the Zacks Rank #1 (Strong Buy) List on August 8, 2025.
InfuSystem Holdings, Inc. (INFU) Q2 2025 Earnings Call Transcript
InfuSystem Holdings, Inc. (NYSE:INFU ) Q2 2025 Earnings Conference Call August 5, 2025 9:00 AM ET Company Participants Barry G. Steele - Executive VP & CFO Carrie A.
InfuSystems Holdings, Inc. (INFU) Tops Q2 Earnings Estimates
InfuSystems Holdings, Inc. (INFU) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.03 per share a year ago.
Is the Options Market Predicting a Spike in InfuSystems Holdings Stock?
Investors need to pay close attention to InfuSystems Holdings stock based on the movements in the options market lately.
InfuSystem: Investments Are Starting To Pay Off
InfuSystem offers integrated clinic-to-home healthcare solutions, leveraging strong payer networks, strategic partnerships, and economies of scale to drive recurring revenue and margin expansion. Recent growth is fueled by diversification into wound care and biomedical services, with Q1 showing double-digit Patient Services revenue growth and record adjusted EBITDA margins. The company's valuation is attractive, trading at just 5.4x FY25 EV/EBITDA, with limited tariff or economic cycle risk and capital spending expected to moderate.
InfuSystem Holdings, Inc. (INFU) Q1 2025 Earnings Call Transcript
InfuSystem Holdings, Inc. (NYSE:INFU ) Q1 2025 Earnings Call May 8, 2025 9:00 AM ET Company Participants Joe Dorame - Managing Partner Richard Dilorio - CEO Barry Steele - EVP and CFO Carrie Lachance - President and COO Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Unidentified Analyst - Craig-Hallum Capital Group Jim Sidoti - Sidoti & Company Anderson Schock - B. Riley Securities Operator Good day and welcome to the InfuSystem Holdings, Inc. Reports First Quarter 2025 Financial Results Conference Call.
InfuSystems Holdings, Inc. (INFU) Reports Q1 Loss, Tops Revenue Estimates
InfuSystems Holdings, Inc. (INFU) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.05 per share a year ago.
InfuSystem Holdings, Inc. (INFU) Q4 2024 Earnings Call Transcript
InfuSystem Holdings, Inc. (NYSE:INFU ) Q4 2024 Results Conference Call March 4, 2025 9:00 AM ET Company Participants Joe Dorame - Managing Partner Rich Dilorio - Chief Executive Officer Barry Steele - Chief Financial Officer Carrie Lachance - President and Chief Operating Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Kyle Bauser - B. Riley Securities Jim Sidoti - Sidoti & Company Operator Good day, and welcome to the InfuSystem Holdings Inc. Reports Fourth Quarter and Full Year 2024 Financial Results Conference Call.
InfuSystems Holdings, Inc. (INFU) Misses Q4 Earnings and Revenue Estimates
InfuSystems Holdings, Inc. (INFU) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to break-even earnings per share a year ago.
